SOUTH CAROLINA – September 30, 2025 – NeuroHope Therapeutics Inc. is a pharmaceutical company co-founded by Clemson University’s bioengineering faculty. NeuroHope specializes in developing nanotherapeutics that can locally deliver drugs to damaged, diseased or degenerating regions of the central nervous system (CNS). Each year, acute spinal cord injury (SCI) impacts approximately 17,000 new patients in the United States and 250-500,000 worldwide, while acute traumatic brain injury (TBI) affects approximately 2.5 million people in the United States and 10-60 million worldwide. Currently, there is no FDA-approved therapy for these patients. Therefore, NeuroHope’s goal is to develop nanotherapeutics that reduce neuroinflammation, mitigate progressive neurodegeneration, increase functional recovery and improve quality of life for people who are living with SCI and TBI.
Solutions
Patent care following CNS trauma, such as SCI and TBI, consists of management and rehabilitation. While the drug rolipram has potential therapeutic benefit for both SCI and TBI, its clinical translation has been limited by challenges with solubility and adverse side effects from high systemic doses. NeuroHope Therapeutics Inc. has developed a proprietary graft copolymer [PgP] that can:
- Increase the water solubility of rolipram (~7 times).
- Allow sustained local delivery in the CNS (over 7 days).
- Remain stable at room temperature over 3 months in suspension.
- Avoid systemic side effects such as emesis, arteritis and effects on endocrine function and hormonal balance.
Strengths
- Patented (2 U.S. Patents: 10,232,050B1 and 11,633,355 B2) technology developed by founder.
- Over $4.5 million in federal, state and foundation funding, including NIH, DoD, VA, SC-SCIRF and Craig H. Neilsen Foundation.
- Over 20 peer-reviewed publications and over 70 international and national conference proceedings related to technology.
- One single administration of nanotherapeutics elicits motor and cognitive function in rat acute SCI and TBI models.
Meet the Co-Founders

From left to right:
Ken Webb, Ph.D. | President
Jeoung Soo Lee, Ph.D. | Chief Technology Officer